News
Premier Inc. Pursues Crucial Strategies to Get Supplies, Enable Care Delivery During COVID-19
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, is coordinating across the industry to help solve the supply chain challenges presented by COVID-19. Success will rely on
Premier Inc. Survey: As COVID-19 Spreads to New Hotspots, Hospitals Should Prepare for up to a 17X Surge in Supply Demand
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today released survey results quantifying the surge capacity needed for personal protective equipment (PPE) and other supplies
Premier Inc. Data Shows Drugs Essential to Providing Care for COVID-19 Patients Quickly Slipping into Shortage
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today released data finding that 15 drugs essential to providing care for COVID-19 patients are currently in or very near
QIAGEN Receives U.S. FDA EUA for QIAstat-Dx test kit, First and Only Syndromic Solution Integrating Detection of SARS-CoV-2 Coronavirus
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its newly developed
QIAGEN erhält als erste und bisher einzige syndromische Testoption Notfallzulassung der FDA für QIAstat-Dx-Testpanel zum Nachweis des Coronavirus SARS-CoV-2
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, dass es von der US-amerikanischen Arzneimittelzulassungsbehörde FDA eine Notfallzulassung (Emergency Use Authorization) für
Update on 92nd Vifor Pharma Ltd. Annual General Meeting
Regulatory News:
Vifor Pharma confirmed that it will hold its Annual General Meeting (AGM) on 14 May, 2020, as planned. In view of the current situation and based on Art. 6a of Ordinance 2
Update zur 92. Generalversammlung der Vifor Pharma AG
Regulatory News:
Vifor Pharma hat bestätigt, dass die Generalversammlung des Unternehmens wie geplant am 14. Mai 2020 abgehalten wird. Aufgrund der aktuellen Situation und im Einklang mit Art. 6a
LivaNova to Host Conference Call for First Quarter 2020 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first quarter 2020 results on Wednesday, April 29, 2020 at 1 p.m
Charles River Laboratories and Deciphex Form a Partnership to Enhance Drug Discovery & Development With Digital Pathology
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a partnership with Deciphex, a leader in preclinical digital pathology software-as-a-service.
Gemeinsamer Bundesausschuss beschließt Aufnahme von TTFields in die Richtlinie Methoden Vertragsärztlicher Versorgung (MVV-RL)
Novocure (NASDAQ: NVCR) gab heute bekannt, dass der Gemeinsame Bundesausschuss (G-BA) die Ergänzung der MVV-RL um die Methode Tumortherapiefelder (TTFields) beschlossen hat. Optune ist somit für
LivaNova Autonomic Regulation Therapy for Heart Failure Findings to be Presented at American College of Cardiology and World Congress of Cardiology Virtual Meeting
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced two abstracts focused on implantable neuromodulation technology for patients with heart
Xencor and Vir Biotechnology Enter License Agreement for Use of Xtend™ XmAb® Antibody Technology in Investigational Antibodies to Treat COVID-19
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced it has entered
QIAGEN ernennt Thierry Bernard zum Chief Executive Officer
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Ernennung von Thierry Bernard zum Chief Executive Officer bekannt gegeben.
Zusätzlich hat eine gemeinsame Sitzung des
QIAGEN Names Thierry Bernard as Chief Executive Officer
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Thierry Bernard has been named Chief Executive Officer.
Additionally, a Joint Meeting of the Supervisory Board and the
QIAGEN Releases QIAstat-Dx Test Kit to the U.S. as First Syndromic Test for Detection of SARS-CoV-2 Coronavirus Under New FDA Policy
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has begun shipments to the United States of its new QIAstat-Dx Respiratory SARS-CoV-2 Panel test to aid in diagnosing
QIAGEN bietet ersten syndromischen QIAstat-Dx-Test zum Nachweis des Coronavirus SARS-CoV-2 in den USA unter neuen FDA Richtlinien an
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute erste Lieferungen des neu entwickelten QIAstat-Dx-SARS-CoV-2-Atemwegspanel zur Diagnose von Patienten mit COVID-19-Infektion in die USA
German Federal Joint Committee Updates Medical Care Directive to include Tumor Treating Fields, establishing National Reimbursement for Optune in Germany
Novocure (NASDAQ: NVCR) today announced that the German Federal Joint Committee, or G-BA, has updated its directive for Contracted Medical Care to include Tumor Treating Fields, establishing
Novocure Announces Optune Lua™ as the Brand Name for the NovoTTF-100L™ System
Novocure (NASDAQ: NVCR) announced today that Optune Lua is the brand name for the NovoTTF-100L System in malignant pleural mesothelioma (MPM). The U.S. Food and Drug Administration (FDA) previously
QIAGEN führt in Europa QIAstat-Dx-Testkit zur Erkennung des neuartigen Coronavirus SARS-CoV-2 nach erfolgter CE-Kennzeichnung ein
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, dass das neu entwickeltes QIAstat-Dx-SARS-CoV-2-Atemwegs-Panel die CE-Kennzeichnung für den Verkauf als In-vitro-Diagnosetest
QIAGEN launches QIAstat-Dx test kit for detection of SARS-CoV-2 coronavirus in Europe following CE marking
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has obtained CE marking for its newly developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test to be sold as an in vitro
QIAGEN Dramatically Ramping Up Global Production Capacity for RNA Extraction Kits for Use in Detection of SARS-CoV-2 Coronavirus
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to dramatically ramp up global production capacity of RNA extraction kits that are used as part of workflows around the
Premier Inc. Survey: More Than Two-Thirds of Senior Living Facilities Say They Can’t Access Personal Protective Equipment Needed for COVID-19 Containment Plans
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today released survey results finding that more than two-thirds of senior living facilities in the United States cannot obtain
Chemed Corporation’s Board of Directors Authorizes an Additional $250 Million for Stock Repurchase
Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has formally authorized an additional $250 million for stock repurchase under Chemed’s existing share repurchase program
QIAGEN Gains BARDA Funding for Approval Process of QIAstat-Dx Test Kit for SARS-CoV-2 Coronavirus
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it will develop a new QIAstat-Dx test kit to differentiate the novel SARS-CoV-2 coronavirus from 21 other serious respiratory